EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy

Junyi He, Yingxin Liu, Xiaoqing Wang, Ruiting Song, Jingze Zhang, Butuo Li, Haohua Wang, Jinming Yu, Linlin Wang

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.02.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Junyi He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shando…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shandong Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Thoracic radiotherapy (RT) is now widely used in the treatment of advanced non-small cell lung cancer (NSCLC) as palliative, consolidative or radical therapy. However, RT adversely impacts the immune system, which can be evaluated by calculating the estimated dose of radiation to immune cells (EDRIC). We evaluated the prognostic impact of the EDRIC in patients with advanced NSCLC who received immunotherapy and thoracic RT. METHODS: We retrospectively enrolled 152 stage IV NSCLC patients who had received first-line immunotherapy and thoracic RT. EDRIC was a model developed by Jin et al., calculated using the number of radiotherapy fractions, mean lung dose, mean heart dose, and mean body dose. Spearman's rank correlation was used to assess the correlations between variables. The relationships of EDRIC (≥5.7 Gy vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyHumansFemaleMaleRetrospective StudiesAgedMiddle AgedNeoplasm StagingPrognosisAged, 80 and overAdultFollow-Up StudiesSurvival RateRadiotherapy Dosage

Stichwörter der Autor:innen

EDRICImmunologyRetrospective studiesStage IVThoracic radiotherapy

Autor:innen und Institutionen

  • Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, S…
  • Department of Portal Hypertension, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, China.
  • Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Acad…

Förderung

  • Shandong Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

He, J., Liu, Y., Wang, X., Song, R., Zhang, J., Li, B., Wang, H., Yu, J., & Wang, L. (2025). The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.02.006

Vancouver

He J, Liu Y, Wang X, Song R, Zhang J, Li B, et al. The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.02.006

BibTeX
@article{He2025,
  author = {He, Junyi and Liu, Yingxin and Wang, Xiaoqing and Song, Ruiting and Zhang, Jingze and Li, Butuo and Wang, Haohua and Yu, Jinming and Wang, Linlin},
  title = {The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.02.006}
}
Kostenlos starten →